Cardio-Oncology is affiliated with the International Cardio-Oncology Society (ICOS).
Articles
Page 1 of 4
-
Citation: Cardio-Oncology 2023 9:43
-
Surveillance cardiopulmonary exercise testing can risk-stratify childhood cancer survivors: underlying pathophysiology of poor exercise performance and possible room for improvement
Asymptomatic childhood cancer survivors (CCS) frequently show decreased exercise performance. Poor exercise performance may indicate impaired future cardiovascular health.
Citation: Cardio-Oncology 2023 9:42 -
Cardiovascular disease incidence rates: a study using routinely collected health data
There is substantial evidence that systemic anticancer therapies and radiotherapy can increase the long-term risk of cardiovascular disease (CVD). Optimal management decisions for cancer patients therefore nee...
Citation: Cardio-Oncology 2023 9:41 -
Cardiac electrical abnormalities in childhood acute lymphoblastic leukemia survivors: a systematic review
The aim was to provide evidence about the prevalence, incidence, and risk factors of cardiac electrical abnormalities in childhood acute lymphoblastic leukemia (ALL) survivors.
Citation: Cardio-Oncology 2023 9:40 -
Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer
Percutaneous left atrial appendage occlusion (LAAO) has been rapidly evolving since FDA’s approval in 2015 and has become more of a same-day-discharge procedure. Cancer patient with atrial fibrillation/flutter...
Citation: Cardio-Oncology 2023 9:39 -
Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that is currently the first-line treatment for metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) due to its favorabl...
Citation: Cardio-Oncology 2023 9:38 -
Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology
Millions of cancer survivors are at risk of cardiovascular diseases, a leading cause of morbidity and mortality. Tools to potentially facilitate implementation of cardiology guidelines, consensus recommendatio...
Citation: Cardio-Oncology 2023 9:37 -
Outcomes of patients with active cancers and pre-existing cardiovascular diseases infected with SARS-CoV-2
To determine the impact of acute SARS-CoV-2 infection on patient with concomitant active cancer and CVD.
Citation: Cardio-Oncology 2023 9:36 -
Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system
Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients. Despite proven efficacy of the monoclonal antibodies, cardiov...
Citation: Cardio-Oncology 2023 9:35 -
Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis
Immune checkpoint inhibitor (ICI) myocarditis is associated with significant mortality risk. Electrocardiogram (ECG) changes in ICI myocarditis have strong prognostic value. However the impact of complete hear...
Citation: Cardio-Oncology 2023 9:34 -
Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
Men diagnosed with prostate cancer are at risk for competing morbidity and mortality due to cardiometabolic disease given their advanced age at diagnosis, high prevalence of pre-existing risk factors, and rece...
Citation: Cardio-Oncology 2023 9:33 -
Screening and management of dyslipidemia in oncologic patients undergoing cardiotoxic therapies: results from an Italian survey
Baseline cardiovascular risk factors correction is recommended in all cancer patients undergoing potentially cardiotoxic therapies. Despite available guidelines, real-world data on dyslipidemia prevalence and ...
Citation: Cardio-Oncology 2023 9:32 -
Simultaneous exercise stress cardiac magnetic resonance and cardiopulmonary exercise testing to elucidate the Fick components of aerobic exercise capacity: a feasibility and reproducibility study and pilot study in hematologic cancer survivors
Patients treated for hematologic malignancy often experience reduced exercise capacity and increased fatigue; however whether this reduction is related to cardiac dysfunction or impairment of skeletal muscle o...
Citation: Cardio-Oncology 2023 9:31 -
Cardiovascular toxicities after anthracycline and VEGF-targeted therapies in adolescent and young adult cancer survivors
Cancer survival rates have been steadily improving in the adolescent and young adult (AYA) population, but survivors are at increased risk for cardiovascular disease (CVD). The cardiotoxic effects of anthracyc...
Citation: Cardio-Oncology 2023 9:30 -
Atrial fibrillation in cancer survivors – a systematic review and meta-analysis
Atrial fibrillation (AF) is a common cardiac complication during cancer treatment. It is unclear if cancer survivors have increased AF risk when compared to the population. AF screening is now recommended in p...
Citation: Cardio-Oncology 2023 9:29 -
Late-stage diagnosis of carcinoid heart disease due to lack of access to health care
Carcinoid syndrome (CS) is a unique constellation of symptoms caused by release of vasoactive substances from neuroendocrine tumors (Pandit et al., StatPearls, 2022). Neuroendocrine tumors are rare with an ann...
Citation: Cardio-Oncology 2023 9:28 -
Mediastinal gray zone lymphoma in a pregnant woman presenting with cardiac tamponade
Mediastinal gray zone lymphoma is a newly recognized rare B cell neoplasm, which is challenging in diagnosis and treatment.
Citation: Cardio-Oncology 2023 9:27 -
Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
25% of all breast cancer patients have HER-2 overexpression. Breast Cancer patients with HER-2 overexpression are typically treated with HER-2 inhibitors such as Trastuzumab. Trastuzumab is known to cause a de...
Citation: Cardio-Oncology 2023 9:26 -
The association of QTc prolongation with cardiovascular events in cancer patients taking tyrosine kinase inhibitors (TKIs)
To investigate the association between stages of QTc prolongation and the risk of cardiac events among patients on TKIs.
Citation: Cardio-Oncology 2023 9:25 -
Quantitative assessment of radiotherapy-induced myocardial damage using MRI: a systematic review
To determine the role of magnetic resonance imaging (MRI)-based metrics to quantify myocardial toxicity following radiotherapy (RT) in human subjects through review of current literature.
Citation: Cardio-Oncology 2023 9:24 -
Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis
Biomarkers represent a potential tool to identify individuals at risk for anthracycline-induced cardiotoxicity (AICT) prior to symptom onset or left ventricular dysfunction.
Citation: Cardio-Oncology 2023 9:23 -
Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The mos...
Citation: Cardio-Oncology 2023 9:22 -
Effect of insulin resistance on CAC scores in cancer survivors
Many ca. survivors exhibit signs of IR, an important risk factor for the development of CAD. CAC scans offer a risk assessment of CV disease before cardiac damage has occurred. We investigated how IR affects C...
Citation: Cardio-Oncology 2023 9:21 -
Detection of right ventricular dysfunction by three – dimensional echocardiography and two - dimensional speckle tracking in breast cancer patients receiving anthracycline- based chemotherapy
Despite the cardiotoxic effect of anthracycline on the left ventricle (LV) was totally identified. The assessment of the anthracycline effect on the right ventricle(RV) by conventional echocardiography was a c...
Citation: Cardio-Oncology 2023 9:20 -
Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer
Though the incidence of atrial fibrillation (AF) is increased in patients with cancer, the effectiveness of catheter ablation (CA) for AF in patients with cancer is not well studied.
Citation: Cardio-Oncology 2023 9:19 -
Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study
Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute co...
Citation: Cardio-Oncology 2023 9:18 -
Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker
Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography asso...
Citation: Cardio-Oncology 2023 9:17 -
A novel cardio-oncology service line model in optimizing care access, quality and equity for large, multi-hospital health systems
Despite the rapid growth of cardio-oncology as a subspecialty, cancer patients are still underserved from a cardiovascular perspective. A new care model is needed to integrate comprehensive cardio-oncology car...
Citation: Cardio-Oncology 2023 9:16 -
Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression
Immune checkpoint inhibitors (ICIs) are currently widely used for treatment of various types of cancers. ICI-induced myocarditis, though uncommon, accounts for high risk of major adverse cardiac events and mor...
Citation: Cardio-Oncology 2023 9:15 -
Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance
Immune checkpoint inhibitor (ICI) myocarditis is associated with high morbidity and mortality. While endomyocardial biopsy (EMB) is considered a gold standard for diagnosis, the sensitivity of EMB is not well ...
Citation: Cardio-Oncology 2023 9:14 -
Rationale and design of a cardiac safety study for reduced cardiotoxicity surveillance during HER2-targeted therapy
Echocardiograms are recommended every 3 months in patients receiving human epidermal growth factor 2 (HER2)-targeted therapy for surveillance of left ventricular ejection fraction (LVEF). Efforts to tailor tre...
Citation: Cardio-Oncology 2023 9:13 -
The association of preoperative high-sensitivity cardiac troponin i and long-term outcomes in colorectal cancer patients received tumor resection surgery
This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients.
Citation: Cardio-Oncology 2023 9:12 -
Endothelial function measured by peripheral arterial tonometry in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy: a pilot study
Arterial occlusive events are an emerging problem in patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy. Endothelial cell damage is thought to play an important role...
Citation: Cardio-Oncology 2023 9:11 -
Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis
Cancer patients receiving chemotherapy have an increased risk of cardiovascular complications. This limits the widespread use of lifesaving therapies, often necessitating alternate lower efficacy regimens, or ...
Citation: Cardio-Oncology 2023 9:10 -
Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options,...
Citation: Cardio-Oncology 2023 9:9 -
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis
Several cohort studies aimed at demonstrating an increased risk of cancer incidence and mortality in patients with a pre-existing diagnosis of heart failure (HF); however, conflicting results have been reporte...
Citation: Cardio-Oncology 2023 9:8 -
Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design
The many improvements in cancer therapies have led to an increased number of survivors, which comes with a greater risk of consequent/subsequent cardiovascular disease. Identifying effective management strateg...
Citation: Cardio-Oncology 2023 9:7 -
Malignant cancer may increase the risk of all-cause in-hospital mortality in patients with acute myocardial infarction: a multicenter retrospective study of two large public databases
Acute myocardial infarction (AMI) and cancer are diseases with high morbidity and mortality worldwide, bringing a serious economic burden, and they share some risk factors. The purpose of this study was to det...
Citation: Cardio-Oncology 2023 9:6 -
Functional testing, coronary artery calcifications, and outcomes in Hodgkin lymphoma survivors treated with chest radiation
Consensus guidelines recommend periodic screening for coronary artery disease (CAD) in Hodgkin lymphoma (HL) survivors treated with radiation therapy (RT) to the chest. However, the prognostic utility of scree...
Citation: Cardio-Oncology 2023 9:5 -
Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report
Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its ...
Citation: Cardio-Oncology 2023 9:4 -
Cardiac hemangioma presenting as a primary cardiac tumor
Cardiac hemangiomas are very rare benign cardiac tumors. They can present at any age and clinical presentation varies according to location and size. We encountered an 87-year-old woman with a left atrial hema...
Citation: Cardio-Oncology 2023 9:3 -
Left atrial appendage volume as a prognostic Indicator of long-term mortality in Cancer survivors treated with thoracic radiation
Cancer survivors with prior chest radiation therapy (CXRT) frequently present with atrial fibrillation, heart failure, and have higher overall long-term mortality. There are no data examining the utility of le...
Citation: Cardio-Oncology 2023 9:2 -
Late cardiac events after allogeneic stem cell transplant: incidence, risk factors, and impact on overall survival
There is limited data on the impact of cardiac disease on long term outcomes of allogeneic stem cell transplant (alloSCT). Our study aims to describe the incidence of late cardiac events after alloSCT, identif...
Citation: Cardio-Oncology 2023 9:1 -
Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study
Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer ...
Citation: Cardio-Oncology 2022 8:23 -
Acute ST-segment elevations following paclitaxel administration for uterine cervical cancer: a case report and literature review
Paclitaxel-induced cardiac ischemia is a rare but life-threatening complication. Although it may be difficult to distinguish from hypersensitivity or infusion reactions, it should not be overlooked. We herein ...
Citation: Cardio-Oncology 2022 8:22 -
The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment
The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events (cvAEs) by pres...
Citation: Cardio-Oncology 2022 8:21 -
Outcomes of malignancy in adults with congenital heart disease: a single center experience
Malignancy is known to be a major cause of death in adult congenital heart disease (ACHD). However, data regarding cardiovascular and cancer-related outcomes in ACHD are lacking.
Citation: Cardio-Oncology 2022 8:20 -
Exercise-induced Brugada pattern and ventricular tachycardia during Capecitabine treatment
We report the case of a 59-year-old female patient with no previous cardiovascular disease treated for Breast cancer with Capecitabine. Shortly after starting treatment, she developed recurrent angina. An exer...
Citation: Cardio-Oncology 2022 8:19 -
Case report: challenges in monitoring and treatment of anthracycline induced cardiotoxicity in young adults with osteosarcoma
Neo(adjuvant) systemic treatment regimens containing anthracyclines such as doxorubicin cause a significant risk of heart failure. These regimens are one of the corner stones of osteosarcoma treatment, and the...
Citation: Cardio-Oncology 2022 8:18 -
Echocardiographic strategy for early detection of cardiotoxicity of doxorubicin: a prospective observational study
Cancer chemotherapy using anthracyclines is associated with cardiotoxicity (CTX), and left ventricular ejection fraction (LVEF) analysis is not sensitive to early cardiotoxic changes. Left ventricular global l...
Citation: Cardio-Oncology 2022 8:17
Follow
Annual Journal Metrics
-
2022 Citation Impact
3.3 - 2-year Impact Factor
0.977 - SNIP (Source Normalized Impact per Paper)
0.790 - SJR (SCImago Journal Rank)2022 Speed
10 days submission to first editorial decision for all manuscripts (Median)
130 days submission to accept (Median)2022 Usage
162,991 downloads
534 Altmetric mentions
On the blog
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
-
Institutional membership
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).